Iwagaki H, Fuchimoto S, Orita K
First Department of Surgery, Okayama University Medical School, Japan.
J Med. 1988;19(1):21-31.
Fresh surgical explants of solid tumors obtained from 50 patients were tested against six chemotherapeutic agents in the in vivo subrenal capsule assay. Control growth adequate to meet evaluable assay criteria was obtained in 36 of 50 tumors (72.0%). With activity criteria set at current drug screening levels as a change in modifidd PAPAN score in less than or equal to -2.0 for the SRC assay, 36.1% of the human tumors evaluable and 11.6% of drugs tested were sensitive, respectively. Our research reveals that gastric cancers respond to drugs about 2.5-fold higher than colorectal cancers. Comparisons were made of the drug sensitivity in terms of histologic differentiation, and it was strongly suggested that the sensitivity of the poorly differentiated type was higher than that of well or moderately differentiated type.
从50例患者获取的实体瘤新鲜手术切除组织在体内肾包膜下试验中针对六种化疗药物进行了测试。50个肿瘤中有36个（72.0%）获得了足以满足可评估试验标准的对照生长。将活性标准设定为当前药物筛选水平，即SRC试验中改良巴氏评分变化小于或等于-2.0，可评估的人类肿瘤和所测试药物的敏感率分别为36.1%和11.6%。我们的研究表明，胃癌对药物的反应比结直肠癌高约2.5倍。对不同组织学分化的药物敏感性进行了比较，强烈提示低分化型的敏感性高于高分化或中分化型。
